Prime Medicine Shares Rise 21% as PM577a Trial Dosing Begins
Prime Medicine said the first patient has been dosed in a Phase 1/2 trial of PM577a, an investigational in vivo prime editor for H1069Q-mutated Wilson disease. Shares rose 21% to $5.27, after reaching a 52-week high earlier in the session.